EpyGenix: Fishing for best in class in epilepsy

EpyGenix has leveraged its animal model of Dravet syndrome to identify three repurposed molecules that have shown high levels of preclinical efficacy. The biotech is hoping the well-established safety profiles of each molecule gives them best-in-class potential.

EpyGenix Therapeutics Inc.’s pipeline was identified using a zebrafish screening model created in the lab of Scott Baraban at the University of California San Francisco. ...